BPTSY (Biophytis) 3-Year ROIIC % : -400.96% (As of Dec. 2024)


BPTSY Biophytis SA BPTSY
18 GF Score
Price $0.25
! 5 Warning Signs
View Full Analysis

What is Biophytis 3-Year ROIIC %?

Biophytis BPTSY 18 3-Year ROIIC % is -400.96 as of Dec. 2024. GuruFocus rates BPTSY with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 1,323 Biotechnology companies, Biophytis ranks worse than 87.15% on this metric.

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Biophytis's 3-Year ROIIC % for the quarter that ended in Dec. 2024 was -400.96%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Biophytis's 3-Year ROIIC % or its related term are showing as below:

BPTSY's 3-Year ROIIC % is ranked worse than
87.15% of 1323 companies
in the Biotechnology industry
Industry Median: -4.82 vs BPTSY: -400.96

Biophytis  (OTCPK:BPTSY) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Biophytis 3-Year ROIIC % Related Terms


Biophytis 3-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for Biophytis's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biophytis 3-Year ROIIC % Chart

Biophytis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.02 -93.24 -991.43 4.94 -400.96

Biophytis Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 4.94 0.00 -400.96 0.00

BPTSY vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison

For the Biotechnology subindustry, Biophytis's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biophytis 3-Year ROIIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biophytis's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Biophytis's 3-Year ROIIC % falls into.


BPTSY
18GF Score
Biophytis SA BPTSY
3-Year ROIIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biophytis 3-Year ROIIC % Calculation

Biophytis's 3-Year ROIIC % for the quarter that ended in Dec. 2024 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( -8.899 (Dec. 2024) - -30.299 (Dec. 2021) )/( 14.447 (Dec. 2024) - 20.752 (Dec. 2021) )
=21.4/-6.305
=-339.41%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 3-Year ROIIC % →
What does a 3-Year ROIIC % of -400.96 mean?
Biophytis (BPTSY) has a 3-Year ROIIC % of -400.96 as of Dec. 2024. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Biophytis and its competitors. According to the industry distribution chart, Biophytis ranks #1153 out of 1323 companies in the Biotechnology industry, placing it in the top 87.2%.
Is Biophytis' 3-Year ROIIC % too high?
Biophytis' current 3-Year ROIIC % is -400.96. Based on the distribution chart, Biophytis ranks #1153 out of 1323 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biophytis has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Biophytis' 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biophytis ranks #1153 out of 1323 companies for 3-Year ROIIC %. This places Biophytis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Biophytis and its competitors. Biophytis's current 3-Year ROIIC % is -400.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biophytis stock overvalued right now?
Biophytis (BPTSY) has a current 3-Year ROIIC % of -400.96. The current 3-Year ROIIC % is -400.96. Biophytis' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Biophytis (BPTSY), the current 3-Year ROIIC % is -400.96 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biophytis Business Description

Address BC 9, Batiment A 4eme etage, 4 Place Jussieu, Sorbonne University, Paris, FRA, 75005
Biophytis SA is a France-based clinical-stage biotechnology company engaged in the development of drug candidates for the treatment of age-related and respiratory diseases. The company focuses on therapies that target degenerative processes associated with aging and improve functional outcomes. Its drug candidate, BIO101, is an orally administered small molecule under development for neuromuscular and respiratory indications, including sarcopenia, Duchenne muscular dystrophy (DMD), and respiratory failure.
18GF Score

Get the complete analysis for BPTSY

3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price